MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$68,778
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of series...
Consultant compensation
Accrued expenses and other liabi...
Others
Negative Cash Flow Breakdown
Net loss
Unbilled receivable
Prepaid expenses and other asset...
Transaction costs associated wit...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Change in fair value of liability classified warrants
0
-
35
998
Net loss
-2,570,875
-3,556,415
-2,767,969
-3,729,128
Accrued interest
320
3,089
3,125
3,161
Consultant compensation
646,310
-
414,951
50,717
Stock-based compensation
1,870
8,743
24,339
45,858
Unbilled receivable
416,811
-420,345
415,934
-1,200,568
Prepaid expenses and other assets
251,128
-1,292,926
1,219,459
-779,709
Accounts payable
308,467
-1,663,513
2,709,279
-579,374
Accrued expenses and other liabilities
312,856
-12,633
-280,663
363,308
Depreciation expense
6,533
6,533
6,533
-
Net cash used in operating activities
-1,962,458
-3,500,925
-1,525,833
-1,866,179
Investment in property and equipment
-
-
0
123,643
Net cash flows used in investing activities
-
-
0
-123,643
Proceeds from public offerings
0
-
0
0
Proceeds from warrant exercises, net of issuance costs
0
-
684,358
1,496,854
Proceeds from warrant inducement, net of issuance costs
0
-
0
0
Transaction costs from public offerings
-204,193
-
-
0
Transaction costs associated with warrant inducements
0
-
204,193
5,410
Repayment of convertible notes
0
-
-
-
Proceeds from issuance of series b preferred stock
2,000,000
-
3,975,000
-
Transaction costs associated with series b preferred stock issuance
106,320
-
391,376
-
Repayment of financed insurance premiums
0
63,947
105,013
39,979
Net cash provided by financing activities
1,893,680
-63,947
4,162,969
1,451,465
Decrease in cash and cash equivalents
-68,778
-3,564,872
2,637,136
-538,357
Cash and cash equivalents beginning of period
745,482
4,310,354
1,673,218
3,502,077
Cash and cash equivalents end of period
676,704
745,482
4,310,354
1,673,218
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
series b preferred...
$2,000,000
Transaction costs from
public offerings
-$204,193
(-200.00%↓ Y/Y)
Net cash provided by
financing activities
$1,893,680
(-39.38%↓ Y/Y)
Canceled cashflow
$310,513
Decrease in cash and cash
equivalents
-$68,778
(94.67%↑ Y/Y)
Canceled cashflow
$1,893,680
Consultant compensation
$646,310
(218.36%↑ Y/Y)
Accrued expenses and
other liabilities
$312,856
(-11.07%↓ Y/Y)
Accounts payable
$308,467
(198.16%↑ Y/Y)
Depreciation expense
$6,533
Stock-based compensation
$1,870
(-98.25%↓ Y/Y)
Accrued interest
$320
(-94.76%↓ Y/Y)
something is missing
-$204,193
Transaction costs
associated with series b...
$106,320
Net cash used in
operating activities
-$1,962,458
(55.54%↑ Y/Y)
Canceled cashflow
$1,276,356
Net loss
-$2,570,875
(30.12%↑ Y/Y)
Unbilled receivable
$416,811
(-61.44%↓ Y/Y)
Prepaid expenses and
other assets
$251,128
(21292.24%↑ Y/Y)
Buy us a coffee
Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. (ENSC)